CLDX Celldex Therapeutics Inc.

2.52
-0.06  -2%
Previous Close 2.58
Open 2.64
Price To Book 0.31
Market Cap 34,697,573
Shares 13,768,878
Volume 585,832
Short Ratio
Av. Daily Volume 372,042

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data ASCO June 1, 2019 noted 2/19 CRs + one PR.
CDX-3379
Recurrent/metastatic head and neck squamous cell cancer
Phase 1/2 data presented November 17, 2018 at the Society for Neuro-oncology (SNO) Meeting.
Varlilumab and nivolumab
Solid tumors - cancer
Trial discontinued early March 2016 as unlikely to meet primary endpoint
CDX-110 rindopepimut - ACT IV
Cancer- glioblastoma multiforme (GBM) front line
Phase 2b data released April 16, 2018 - primary endpoint not met.
Glembatumumab vedotin
Metastatic triple negative breast cancers that overexpress gpNMB
Phase 2 presentation at AACR April 15, 2018.
CDX-301
Non-small Cell Lung Cancer (NSCLC)
Phase 1 updated data at AACR April 1, 2019.
CDX-1140
Solid tumors

Latest News

  1. Celldex Therapeutics Appoints Diane C. Young, M.D. as Senior Vice President, Chief Medical Officer
  2. Celldex Presents Data From CDX-3379 Study at ASCO, Stock Down
  3. The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-Tender Offer
  4. Celldex Announces Data from CDX-3379 Clinical Program Presented at ASCO 2019; Promising Biomarker Strategy Identified for Head and Neck Squamous Cell Carcinoma
  5. The Week Ahead In Biotech: ASCO Presentations In The Spotlight
  6. Wall Street Sees 3 Falling Knives Rebounding Within 52 Weeks
  7. Celldex Therapeutics Continues to Stretch Out Its Cash and Advance Its Pipeline
  8. Celldex Therapeutics (CLDX) Reports Q1 Loss, Tops Revenue Estimates
  9. Celldex: 1Q Earnings Snapshot
  10. Celldex Provides Corporate Update and Reports First Quarter 2019 Results
  11. Celldex Therapeutics (CLDX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
  12. Celldex (CLDX) Down 5.7% Since Last Earnings Report: Can It Rebound?
  13. Celldex Presents Positive Interim Results from Phase 1 Study of CD40 Agonist CDX-1140 at American Association for Cancer Research (AACR) Annual Meeting 2019
  14. Celldex Presents Promising Data from CDX-527 Bispecific and TAM Receptor Programs at American Association for Cancer Research (AACR) Annual Meeting 2019
  15. Is Celldex Therapeutics (CLDX) Stock Outpacing Its Medical Peers This Year?
  16. Edited Transcript of CLDX earnings conference call or presentation 7-Mar-19 9:30pm GMT
  17. Celldex (CLDX) Q4 Loss Narrower than Expected, Sales Beat
  18. Celldex Therapeutics' Cost-Cutting and Reverse Stock Split Help Keep It Rolling
  19. Celldex Therapeutics, Inc (CLDX) Q4 2018 Earnings Conference Call Transcript
  20. Celldex Provides Corporate Update and Reports Full Year 2018 Results